Amgen 2010 Annual Report Download - page 151

Download and view the complete annual report

Please find page 151 of the 2010 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

Shelf registration statements and other facilities
As of December 31, 2010, we have a commercial paper program that allows us to issue up to $2.3 billion of
unsecured commercial paper to fund our working capital needs. At December 31, 2010, no amounts were
outstanding under our commercial paper program.
As of December 31, 2010, we have a $2.3 billion syndicated, unsecured, revolving credit facility which
matures in November 2012 and is available for general corporate purposes or as a liquidity backstop to our
commercial paper program. Annual commitment fees for this facility are 0.05% based on our current credit rating.
As of December 31, 2010, no amounts were outstanding under this facility.
We have filed a shelf registration statement with the SEC, which allows us to issue an unspecified amount of
debt securities; common stock; preferred stock; warrants to purchase debt securities, common stock, preferred stock
or depository shares; rights to purchase common stock or preferred stock; securities purchase contracts; securities
purchase units and depository shares. Under this registration statement, all of the securities available for issuance
may be offered from time to time with terms to be determined at the time of issuance. This shelf registration expires
in April 2011.
As of December 31, 2010, we have $400 million remaining under a shelf registration statement that was
established in 1997. In connection with this shelf registration, we established a $400 million medium-term note
program under which medium-term debt securities may be offered from time to time with terms to be determined at
the time of issuance. As of December 31, 2010, no securities were outstanding under this medium-term note
program.
Certain of our financing arrangements contain non-financial covenants and we were in compliance with all
applicable covenants as of December 31, 2010. None of our financing arrangements contain any financial
covenants.
Contractual maturities of long-term debt obligations
The aggregate contractual maturities of all long-term debt obligations due subsequent to December 31, 2010
are as follows (in millions):
Maturity date Amount
2011(1) ...................................................................... $ 2,500
2012(2) ...................................................................... 84
2013(3) ...................................................................... 2,500
2014 ....................................................................... 1,000
2015 ....................................................................... —
Thereafter.................................................................... 7,600
Total...................................................................... $13,684
(1) This amount represents the principal amount due for our 2011 Convertible Notes after full accretion of the debt
discount.
(2) This amount represents the accreted value of our zero coupon convertible notes due in 2032 as of March 1,
2012, the next date on which holders may put the debt to us for repayment.
(3) This amount represents the principal amount due for our 2013 Convertible Notes after full accretion of the debt
discount.
F-29
AMGEN INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)